Table 1.
Comparison of baseline data between those who received evolocumab and controls.
| Control group (n = 160) | Evolocumab group (n = 149) | χ 2/t/Z | p value | |
|---|---|---|---|---|
| Male sex, n (%) | 120 (75.0) | 102 (68.46) | 1.63 | 0.20 |
| Age (years), mean, SD | 64.15, 10.73 | 62.49, 10.45 | 1.38 | 0.17 |
| STEMI, n (%) | 103 (64.38) | 99 (66.44) | 0.15 | 0.70 |
| Old MI, n (%) | 28 (17.50) | 26 (17.45) | <0.01 | 0.99 |
| Diabetes mellitus, n (%) | 58 (36.25) | 57 (38.26) | 0.13 | 0.72 |
| Hypertension, n (%) | 88 (55.00) | 96 (64.43) | 2.85 | 0.09 |
| SBP (mmHg), median (IQR) | 134.00 (123.00–145.00) | 134.00 (123.00–145.00) | −0.14 | 0.89 |
| DBP (mmHg), median (IQR) | 78.00 (70.00–89.00) | 78.00 (70.00–88.75) | −0.60 | 0.55 |
| Atorvastatin, n (%) | 91 (56.88) | 80 (53.69) | 0.32 | 0.57 |
| RAAS inhibitors, n (%) | 143 (89.38) | 126 (84.56) | 1.59 | 0.21 |
| Killip class I, n (%) | 157 (98.13) | 141 (94.63) | 2.74 | 0.10 |
| LVEF (%), median (IQR) | 50.00 (45.00–56.00) | 51.50 (46.00–56.00) | −0.87 | 0.39 |
| NT-pro-BNP (ng/L), median (IQR) | 684.00 (206.20–1582.00) | 719.60 (328.65–1510.00) | −0.57 | 0.57 |
| TNT (ng/mL), median (IQR) | 1.74 (0.64–3.39) | 1.43 (0.43–3.11) | −1.43 | 0.15 |
| Hb (g/L), median (IQR) | 133.00 (125.00–145.00) | 134.00 (122.25–145.00) | −0.01 | 0.99 |
| Hs-CRP (mg/L), median (IQR) | 6.34 (2.25–23.10) | 5.01 (2.13–13.67) | −1.16 | 0.25 |
| HDL-C (mmol/L), median (IQR) | 1.03 (0.87–1.24) | 1.00 (0.83–1.20) | −1.11 | 0.27 |
| LDL-C (mmol/L), median (IQR) | 3.17 (2.51–3.87) | 3.23 (2.43–4.24) | −0.02 | 0.99 |
| Contrast agent (mL), median (IQR) | 140.00 (130.00–150.00) | 140.00 (120.00–150.00) | −0.73 | 0.47 |
| Emergency PCI, n (%) | 103 (64.38) | 99 (66.44) | 0.15 | 0.70 |
| Preoperative hydration, n (%) | 43 (26.88) | 29 (19.46) | 2.37 | 0.12 |
| Postoperative hydration, n (%) | 157 (98.13) | 147 (98.66) | 0.14 | 0.71 |
| Iodixanol, n (%) | 154 (96.25) | 118 (79.19) | 21.29 | <0.01 |
χ 2/t/Z, a test used to compare parameters; SD, standard deviation; STEMI, acute ST-segment elevation myocardial infarction; MI, myocardial infarction; SBP, systolic blood pressure; IQR, interquartile range; DBP, diastolic blood pressure; RAAS, renin-angiotensin-aldosterone system; LVEF, left ventricular ejection fraction; NT-pro-BNP, N-terminal probrain natriuretic peptide; TNT, troponin T; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention.